Eton Pharmaceuticals Plans Phase 2 Mecasermin Trial for Pediatric Epileptic Spasms in Q1 2027

PUBT · 2d ago
Eton Pharmaceuticals Plans Phase 2 Mecasermin Trial for Pediatric Epileptic Spasms in Q1 2027
  • Eton Pharmaceuticals launched ET-900 to evaluate mecasermin for infantile and epileptic spasms, targeting a new use for INCRELEX’s active ingredient.
  • Licensed patent rights from Baylor College of Medicine underpin the program; Eton retains commercial rights, supporting its planned pediatric neurology expansion.
  • An FDA investigational new drug application was submitted for an investigator-sponsored Phase 2 trial, with initial dosing targeted for first-quarter 2027.
  • The University of Chicago-sponsored study will enroll up to 20 patients ages 2-18 with refractory epileptic spasms across three sites.
  • Reported animal research showed reduced spasms, with some animals becoming spasm-free; the planned clinical trial will evaluate efficacy, safety and tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020650PRIMZONEFULLFEED9867635) on November 02, 2026, and is solely responsible for the information contained therein.